Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MAOB | P27338 | 3/20 | 0.49 |
| ▸ | HTR6 | P50406 | 1/20 | 0.47 |
| ▸ | AS3MT | Q9HBK9 | 1/20 | 0.46 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | PPARD | Q03181 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.41 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2175788 | 0.90 | DYRK1A (0.47) | MEN1NPC1RAB9AKMT2AMAOB | |
| SCHEMBL2176044 | 0.88 | MEN1 (0.53) | MEN1NPC1RAB9AKMT2AMAOB | |
| SCHEMBL2175615 | 0.78 | CA12 (0.50) | MEN1NPC1RAB9AKMT2AMAOB | |
| SCHEMBL4328766 | 0.78 | MEN1 (0.61) | MEN1NPC1RAB9AKMT2AMAOB | |
| SCHEMBL7387644 | 0.76 | SRD5A2 (0.50) | MEN1NPC1RAB9AKMT2AMAOB | |
| SCHEMBL28375660 | 0.75 | GRM5 (0.48) | MEN1NPC1RAB9AKMT2AMAOB | |
| SCHEMBL28326780 | 0.75 | KMT2A (0.52) | MEN1NPC1RAB9AKMT2AMAOB | |
| SCHEMBL28995408 | 0.75 | SRD5A2 (0.51) | MEN1NPC1RAB9AKMT2AMAOB | |
| SCHEMBL21614278 | 0.74 | CYP4F2 (0.51) | MEN1NPC1RAB9AKMT2AMAOB | |
| SCHEMBL2176450 | 0.74 | MAPT (0.43) | NPC1RAB9AHTR6L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7973051-B2 | Aminothiazoles as FBPase inhibitors for diabetes | HOFFMAN-LA ROCHE INC. (US) | 2011-07-05 | — | — | US | disclosed |
| CN-101878211-A | Aminothiazole derivs | HOFFMANN LA ROCHE | 2010-11-03 | — | — | CN | disclosed |
| EP-2227468-A1 | AMINOTHIAZOLE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2010-09-15 | — | — | EP | disclosed |
| US-20090143448-A1 | NEW AMINOTHIAZOLES AS FBPASE INHIBITORS FOR DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-04 | — | — | US | disclosed |
| WO-2009068467-A1 | AMINOTHIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143448-A1 | NEW AMINOTHIAZOLES AS FBPASE INHIBITORS FOR DIABETES | FBP1, SLC5A1, DPP4 | MEN1 1402/4885NPC1 2662/4885RAB9A 2410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.